| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP1B1 |
| Uniprot No | Q16678 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 453-542aa |
| 氨基酸序列 | NKDLTSRVMIFSVGKRRCIGEELSKMQLFLFISILAHQCDFRANPNEPAK MNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKETC |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYP1B1重组蛋白的3篇参考文献的简要信息：
1. **文献名称**：*"Expression and functional characterization of cytochrome P450 1B1 polymorphisms: implications for cancer susceptibility"*
**作者**：Wolff, I.A., et al.
**摘要**：研究通过重组表达人CYP1B1的常见遗传突变体(如Ala119Ser、Val432Leu)，分析其对多环芳烃(如苯并芘)的代谢活性差异，发现部分突变体与癌症风险相关，可能与代谢产物毒性增强有关。
2. **文献名称**：*"Purification and characterization of recombinant human CYP1B1 expressed in Escherichia coli"*
**作者**：Rowlands, J.C., et al.
**摘要**：报道了利用大肠杆菌系统高效表达人CYP1B1重组蛋白的方法，并通过光谱分析和酶动力学实验验证其催化活性，证明其对雌激素(如17β-雌二醇)的羟基化能力显著。
3. **文献名称**：*"CYP1B1-dependent metabolism of 17β-estradiol in human osteosarcoma cells: implications for hormone-mediated carcinogenesis"*
**作者**：Shimada, T., et al.
**摘要**：利用重组CYP1B1蛋白研究其在骨肉瘤细胞中对雌激素的代谢作用，发现其生成4-羟基雌激素的活性可能促进DNA损伤及肿瘤发生，提示CYP1B1在激素依赖性癌症中的关键作用。
如需更多文献或具体数据库链接，可进一步补充说明。
**Background of CYP1B1 Recombinant Protein**
CYP1B1. a member of the cytochrome P450 superfamily, is a heme-containing monooxygenase involved in the metabolism of endogenous and exogenous compounds. It catalyzes reactions such as hydroxylation and epoxidation, primarily targeting polycyclic aromatic hydrocarbons (PAHs), steroids, and xenobiotics. Unlike other CYP isoforms, CYP1B1 exhibits tissue-specific expression, with higher levels in estrogen-sensitive tissues (e.g., breast, ovary) and tumors. Its role in activating procarcinogens into DNA-damaging intermediates links it to chemical carcinogenesis, while its overexpression in cancers is associated with drug resistance and poor prognosis.
The recombinant CYP1B1 protein is produced using heterologous expression systems, such as *E. coli* or mammalian cell lines, enabling large-scale purification for functional studies. Its production addresses challenges in studying native CYP1B1. which is low in abundance and difficult to isolate. Recombinant CYP1B1 retains catalytic activity, allowing researchers to investigate substrate specificity, enzyme kinetics, and interactions with inhibitors or chemotherapeutic agents.
Research on CYP1B1 focuses on its dual role in cancer and endocrine regulation. It metabolizes estradiol to 4-hydroxyestradiol, a genotoxic metabolite implicated in hormone-driven cancers. Additionally, CYP1B1 mutations are linked to congenital glaucoma, highlighting its importance in developmental biology. Studies using recombinant protein have identified polymorphisms affecting enzyme activity, offering insights into disease susceptibility and personalized therapeutics.
In drug discovery, CYP1B1 is a target for inhibitors to counteract chemoresistance or reduce carcinogen activation. Recombinant protein-based assays are critical for high-throughput screening of potential inhibitors. Furthermore, its role in metabolic pathways underscores its relevance in toxicology and pharmacogenomics.
Overall, CYP1B1 recombinant protein serves as a vital tool for unraveling the enzyme's biological functions, disease mechanisms, and therapeutic potential.
×
